Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The health and economic repercussions of declining MMR coverage in the United States.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Estimating US savings on outpatient prescription pharmaceuticals from international reference pricing.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The synergy of therapeutic vaccination and timely diagnosis for TB control in high-burden settings: Nunavut as a case study.

Journal of clinical tuberculosis and other mycobacterial diseases·2025
Same author

Racial and Ethnic Disparities in Meningococcal Vaccination Coverage and Disease Burden Among U.S. Adolescents.

The Journal of adolescent health : official publication of the Society for Adolescent Medicine·2025
Same author

Quantifying the mortality and morbidity impact of medicaid work requirements: a modeling study.

Lancet regional health. Americas·2025
Same author

School-Level Gaps in MMR Coverage as the Fuel for Measles Outbreaks.

Annals of internal medicine·2025
Same journal

Erratum for the Research Article "Detecting supramolecular organic nanoparticles during heat wave".

Science (New York, N.Y.)·2026
Same journal

Local signals, systemic decline.

Science (New York, N.Y.)·2026
Same journal

The mechanics of liver regeneration.

Science (New York, N.Y.)·2026
Same journal

Computing in a memory with physics.

Science (New York, N.Y.)·2026
Same journal

Retraction.

Science (New York, N.Y.)·2026
Same journal

Making time.

Science (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

Optimizing influenza vaccine distribution.

Jan Medlock1, Alison P Galvani

  • 1Epidemiology and Public Health, Yale University School of Medicine, 60 College Street, New Haven, CT 06520-8034, USA. medlock@clemson.edu

Science (New York, N.Y.)
|August 22, 2009
PubMed
Summary
This summary is machine-generated.

Optimizing influenza vaccine allocation requires prioritizing schoolchildren and adults aged 30-39. This strategy minimizes deaths, infections, and economic costs by targeting key transmission groups.

More Related Videos

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

Related Experiment Videos

Last Updated: Jun 20, 2026

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers
06:34

An Optimized Hemagglutination Inhibition (HI) Assay to Quantify Influenza-specific Antibody Titers

Published on: December 1, 2017

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
08:52

Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes

Published on: July 26, 2019

Optimization of a Quantitative Micro-neutralization Assay
10:09

Optimization of a Quantitative Micro-neutralization Assay

Published on: December 14, 2016

Area of Science:

  • Public Health
  • Epidemiology
  • Health Economics

Background:

  • Effective public health policies rely on robust assessment criteria for optimization.
  • Influenza pandemics pose significant risks to public health and economies.
  • Vaccine allocation strategies are critical for mitigating influenza's impact.

Purpose of the Study:

  • To determine optimal influenza vaccine allocation strategies.
  • To evaluate different outcome measures for policy optimization.
  • To compare model-based recommendations with existing guidelines.

Main Methods:

  • A mathematical model was developed using survey-based contact and mortality data.
  • The model simulated influenza pandemic scenarios.
  • Optimal vaccine allocation was assessed across five distinct outcome measures.

Main Results:

  • Prioritizing schoolchildren and adults aged 30-39 years is optimal for reducing deaths, infections, and economic costs.
  • Schoolchildren are identified as primary drivers of influenza transmission.
  • Existing U.S. Centers for Disease Control and Prevention recommendations were found to be suboptimal.

Conclusions:

  • Age-specific transmission dynamics are crucial for effective influenza vaccine allocation.
  • Targeting schoolchildren and their parents can significantly reduce disease spread.
  • Policy optimization requires dynamic assessment beyond static recommendations.